GLP-1 drugs and 'Ozempic babies': what the fertility data shows

What did @drpoojagidwani actually say?

Dr. Pooja, who identifies as board-certified in internal and obesity medicine, made three specific claims: the 'Ozempic baby' phenomenon is real, GLP-1 agonists can improve fertility in both men and women, and these drugs can reduce the effectiveness of oral contraceptive pills. She also gave a specific behavioral recommendation: use backup contraception for at least four weeks after starting a dose and four weeks after each dose increase.

The video is short, structured as a public service announcement, and aimed at a general TikTok audience. That context matters. She's not citing studies, she's flagging a safety issue. Whether the underlying claims hold up is a separate question from whether the warning itself is responsible. It largely is.

Does the science back this up?

Mostly, yes, though the fertility improvement claim is better supported in women with PCOS than in the general population, and the male fertility angle is genuinely underexplored.

On the contraceptive effectiveness question: semaglutide delays gastric emptying, which is well-documented. Oral contraceptives depend on reliable gastrointestinal absorption. A 2022 pharmacokinetic analysis published in Clinical Pharmacokinetics (Nauck et al.) confirmed that GLP-1 receptor agonists meaningfully slow gastric emptying, creating a plausible mechanism for reduced OCP absorption. The FDA label for semaglutide (Ozempic/Wegovy) explicitly notes this risk and recommends a barrier method or non-oral contraceptive during the first four weeks of each dose escalation. So her four-week guidance is not invented. It comes directly from regulatory labeling.

On fertility: weight loss itself improves ovulation in women with obesity-related anovulation. GLP-1 agonists also appear to have direct effects on ovarian function in PCOS, independent of weight loss (Elkind-Hirsch et al., 2022, Fertility and Sterility). The 'Ozempic baby' stories circulating online are largely explained by restored ovulation in women who previously assumed they were infertile. That part checks out.

What did they get wrong (or right)?

The male fertility claim is where this video overreaches. Dr. Pooja says GLP-1 agonists can improve fertility 'if you're a male too,' delivered with the same confidence as the female claim. The evidence base here is thin. There are animal studies suggesting GLP-1 receptors exist in testicular tissue, and some small human studies showing modest improvements in testosterone levels with weight loss from GLP-1 drugs. But a direct, well-powered human study showing GLP-1 agonists improve male fertility outcomes, sperm count, motility, or conception rates, does not yet exist in the peer-reviewed literature. Saying 'yes this applies to men too' without that caveat is an overstatement.

What she got right: the contraceptive interaction warning is accurate, clinically relevant, and almost certainly undersaid in clinical practice. Patients starting semaglutide or tirzepatide are often not counseled on this. The four-week guidance aligns with FDA labeling. Giving this warning to a lay audience on a platform where people are actively talking about weight loss medications is genuinely useful public health communication.

What should you actually know?

If you are on oral contraceptives and starting a GLP-1 medication, this is not a hypothetical risk to ignore. The mechanism is real: slower gastric emptying means the pill may not absorb reliably, particularly in the early weeks of treatment or after dose increases. Use a backup method. An IUD, a condom, a progestin-only injectable, these are not impacted by gastric motility the way a daily oral pill is.

If you have PCOS or obesity-related irregular cycles and are starting a GLP-1 drug, do not assume you cannot get pregnant. Women who have had irregular or absent periods for years have reported unexpected pregnancies after starting these medications. This is not a side effect of the drug in the traditional sense. It is the drug working, restoring metabolic function that was disrupted by insulin resistance or excess weight. Talk to your prescriber about contraception before you start, not after.

• GLP-1 drugs are not approved for use during pregnancy. Semaglutide is listed as Pregnancy Category X equivalent under current FDA guidance. Stop the medication and contact your provider immediately if you become pregnant.
• The male fertility claim needs more human data before it should be stated as settled fact.
• Your OCP is not a reliable sole contraceptive during dose escalation on a GLP-1 drug.